Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O’day Sells 15,881 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 15,881 shares of Gilead Sciences stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $175.25, for a total transaction of $2,783,145.25. Following the sale, the chief executive officer owned 566,683 shares of the company’s stock, valued at approximately $99,311,195.75. This represents a 2.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, November 2nd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $169.74, for a total value of $2,546,100.00.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total value of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00.

Gilead Sciences Trading Down 1.7%

NASDAQ GILD opened at $167.47 on Wednesday. The firm has a 50 day simple moving average of $151.77 and a 200-day simple moving average of $140.25. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $175.65. The firm has a market cap of $207.72 billion, a price-to-earnings ratio of -53.00 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.47 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post -1.03 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on GILD. Barclays cut their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Scotiabank boosted their price objective on Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 30th. Truist Financial upped their target price on shares of Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $169.74.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of GILD. PFS Partners LLC increased its position in Gilead Sciences by 101.1% during the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 96 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences in the second quarter valued at $25,000. Laurel Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences during the third quarter valued at $29,000. Kimelman & Baird LLC acquired a new stake in shares of Gilead Sciences during the second quarter valued at $25,000. Finally, Toth Financial Advisory Corp boosted its stake in shares of Gilead Sciences by 85.5% during the third quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain broadly upbeat, with several recent price-target increases, including targets as high as $200. Coverage cites Gilead’s recent execution, HIV franchise and pipeline; a separate estimate of fair value also moved higher. Gilead price target raised to $200 Gilead fair-value estimate
• Positive Sentiment: Gilead plans to present results from more than 50 studies, including late-breaking clinical data and real-world evidence, at HIV Glasgow 2026 on November 8–11. The updates could offer pipeline and franchise catalysts. Gilead HIV Glasgow presentation
• Positive Sentiment: BioNTech said it advanced a planned Phase 3 trial, pending regulatory approval, combining its candidate pumitamig with Gilead’s cancer drug Trodelvy in triple-negative breast cancer. This represents potential progress for Gilead’s oncology collaboration, though the study remains subject to approval. BioNTech quarterly results and update
• Negative Sentiment: Investors bought 16,499 GILD put options, about 107% above typical volume. The jump may signal increased hedging or bearish positioning, although options activity alone does not establish a market view.
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions. Both sales were made under a prearranged Rule 10b5-1 plan, which may temper their significance, but insider selling can still be viewed cautiously by investors. CEO share sale details

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.